Comprehensive Analysis of the CD-19 Antibody Market 2025-2034: Growth Rates, Trends, and Future Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the cd-19 antibody market grown in recent years?
The market size for CD-19 antibodies has significantly expanded in the past few years. The market is projected to increase from $1.75 billion in 2024 to $1.91 billion in 2025, representing a compound annual growth rate (CAGR) of 9.3%. This impressive growth in the historical period can be associated with the escalation in B-cell malignancies cases, adoption of immunotherapy, surge in funding for oncology research, development of CAR-T cell therapies, heightened healthcare awareness, and the broadening scope of personalized medicine.
How is the cd-19 antibody market size expected to evolve during the forecast period?
Predictions indicate robust enlargement of the CD-19 antibody market in the upcoming years, with its value escalating to $2.70 billion in 2029, marking a compound annual growth rate (CAGR) of 9.0%. The surge during the projected period can be credited to rising demand for specialized cancer treatments, an upswing in the application of smart cell therapies, an increase in the incidence of hematologic malignancies, the broadening of healthcare reach in emerging markets, along with progression in next-gen immunotherapies and enhancements in biomanufacturing technologies. The upcoming period is set to witness trends such as advancement in antibody-drug conjugates, evolution of bispecific antibodies, the utilization of AI in antibody formation, enhancements in cell-cell therapy platforms, the uptake of single-use bioreactors, the arrival of nanobody-based treatments, and the introduction of automation in biopharmaceutical production.
Get your cd-19 antibody market report here!
https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report
Which key drivers are propelling the cd-19 antibody market’s growth?
The increasing frequency of B-cell malignancies is projected to boost the expansion of the CD-19 antibody market. B-cell malignancies are a set of cancers that start from abnormal B lymphocytes, including diseases like B-cell lymphomas and leukemias, which harm the immune system and may result in uncontrolled cell growth. This growing occurrence is linked to a variety of factors such as aging population, genetic elements, environmental exposure, lifestyle choices, enhanced detection, and modifications in the immune system. The CD19 antibody works by specially targeting the CD19 protein on the surface of malignant B cells, leading to their eradication while preserving healthy cells and strengthening the body’s immune response. For example, in January 2024, the American Cancer Society, a US-based non-profit organization, estimated that approximately 80,620 individuals in the USA were diagnosed with non-Hodgkin lymphoma, and 20,240 people, including 44,590 men and 36,030 women, were projected to pass away due to non-Hodgkin lymphoma. Thus, the growing frequency of B-cell malignancies is fueling the expansion of the CD-19 antibody market.
What are the market segments in the cd-19 antibody industry?
The CD-19 antibody market covered in this report is segmented –
1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types
2) By Type: Polyclonal, Monoclonal
3) By Route Of Administration: Intravenous, Subcutaneous
4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications
Subsegments:
1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma
2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL
3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL
4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp
Which leading companies are shaping the growth of the cd-19 antibody market?
Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.
What are the key trends shaping the future of the cd-19 antibody market?
Key players in the CD-19 antibody market are striving to introduce technologically advanced solutions, such as genetically engineered autologous T-cell immunotherapy, to improve the effectiveness of cancer therapies, particularly for blood-related cancers. Genetically engineered autologous T-cell therapy involves modifying the patient’s own T-cells to detect and combat cancer cells, before putting them back into the patient’s body to strengthen the immune response against the disease. For example, in November 2024, Autolus Therapeutics plc, an American biopharmaceutical firm, announced that the U.S. FDA had approved AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients who had relapsed or had treatment-resistant B-cell precursor acute lymphoblastic leukemia (ALL). The goal of this treatment is to curb excessive T-cell activation, lessening toxicity and prolonged efficacy of the therapeutic cells. It is administered in split doses on the first and tenth day, with dosage personalized according to bone marrow evaluation before starting therapy.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21130
Which geographic areas are influencing the growth of the cd-19 antibody market?
North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Zollinger-Ellison Syndrome Treatment Global Market Report 2025
Acute Respiratory Distress Syndrome Global Market Report 2025
Global Anesthesia And Respiratory Devices Opportunities And Strategies Global Market Report 2025
https://thebusinessresearchcompany.com/report/anesthesia-and-respiratory-devices-market
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
